Recent Updates
Recently added Catalysts

AtaiBeckley Inc.

ATAI
OvervaluedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$7.35
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ATAI financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.2752W HIGH $7.45
Volume
9.59 M
Value Traded
25.01 M
Short % Float
6.35%
+0.82%Week
+1.52%1 Month
+80.59%3 Month
+106.46%6 Month
-79.43%5 Year
-79.43%All Time

Cash Data

Unlock ATAI cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.73 B
EPS (TTM)
-0.83
P/E Ratio
-
Ent. Value
2.58 B
Total Shares
370.86 M
Float Shares
302.16 M
Insiders
18.53%
Institutions
35.70%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2a data readout
BPL-003 (mebufotenin benzoate)
treatment-resistant depression (TRD)
Breakthrough
Phase 2aSmall MoleculesPsychiatric Disorders
Unlock every ATAI catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ATAI Catalyst Timeline

Dated clinical, regulatory and corporate events for AtaiBeckley Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for AtaiBeckley Inc.

64Total events
8Upcoming
24Tier-1 (high impact)
2024 to 2026Coverage

Upcoming catalysts 2

T3Additional Data
Subscribe to view catalyst details
BPL-003
T1Topline Readout
Subscribe to view catalyst details
BPL-003

Event history 50

▲Last Patient Last VisitVLS-01Trial
Last patient dosed in Phase 2b Elumina trial
treatment-resistant depressionsource ↗
▲Quarterly UpdateCorporate
AtaiBeckley added to Russell 2000 and Russell 3000 Indexes
source ↗
◆Oral PresentationPresentation
7th Annual HCW Neuro Perspectives Hybrid Conference Virtual Presentation
source ↗
◆Oral PresentationPresentation
Oppenheimer CNS and Neuro-Muscular Summit Fireside Chat
source ↗
◆Oral PresentationPresentation
Jefferies Global Healthcare Conference Fireside Chat
source ↗
●Quarterly UpdateCorporate
Q1 2026 financial results
source ↗
◆Oral PresentationPresentation
Panel at Needham Virtual Psychedelics Forum
source ↗
▲Full ResultsEMP-01Clinical Data
Additional Phase 2a results for EMP-01 showing large improvements in SAD
Social Anxiety Disordersource ↗
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
source ↗
▲End Of Phase 2 MeetingBPL-003FDA Meeting
Successful End-of-Phase 2 meeting with FDA for BPL-003
treatment-resistant depressionsource ↗
Unlock the full ATAI catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ATAI actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-03-31EMP-01 Phase 2 topline data readout Phase 2
Unlock 4 more ATAI historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C44 / 100
Pipeline Score
$525M
Pipeline Value
Overvalued
Valuation Signal
9
Drugs Scored
0.2x
rNPV / MCap
AtaiBeckley Inc. carries a moderate pipeline score (44/100), with $847M risk-adjusted pipeline value, led by RL-007 in Cognitive Impairment (Phase 2).
Showing 1 of 9 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
RL-007 Small moleculeCompletedNCT05686239Cognitive Impairment Associated With Schizophrenia (CIAS)Phase 2 COMPLETED 242Apr 9, 2025
Unlock the ATAI pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ATAI program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
EMP-01 Social Anxiety DisorderPhase 2a2026-04-22placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE; 49% PGI-C responders at Day 43 compared to 12% on placebo; 38% reduction on SPIN; 32% reduction on SAFE; LSMD of -11.9 points on LSAS (g=0.45); 49% CGI-I responders at Day 43 compared to 15% on placeboRead MoreAtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderRead More
Scroll for more · summaries link to the source press release
Unlock every ATAI trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ATAI insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
HERSHBERG ROBERTDirectorOption 48,858 48,858 held$1.35 07/07/2026
Unlock the full ATAI insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ATAI

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 1.1 % (57.1 %) 75.98 M 14.42 M 20.15% ( 2.42 M)
Unlock every fund holding ATAI
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ATAI
Shares held by hedge funds each quarter, and who bought or sold.

ATAI Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ATAI option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ATAI option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ATAI options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ATAI ranks across every disease it competes in

Competitive Position is a premium feature
See how ATAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ATAI News

About AtaiBeckley Inc.

New York, NY 99 employees ataibeckley.com
HeadquartersC/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119
BIOPHARMAWATCH ELITE PLUS
Trade the next ATAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime